The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of the treatment effect between lenvatinib and atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in pathologically diagnosed metabolic dysfunction–associated steatotic liver disease.
 
Hirokazu Takahashi
No Relationships to Disclose
 
Yuichi Koshiyama
No Relationships to Disclose
 
Yasuhide Mitsumoto
No Relationships to Disclose
 
Takashi Kobayashi
No Relationships to Disclose
 
Hideki Hayashi
No Relationships to Disclose
 
Taeang Arai
No Relationships to Disclose
 
Koji Sawada
No Relationships to Disclose
 
Michihiro Nonaka
No Relationships to Disclose
 
Takashi Nakahara
No Relationships to Disclose
 
Kengo Tomita
No Relationships to Disclose
 
Takanori Ito
No Relationships to Disclose
 
Kazuo Notsumata
No Relationships to Disclose
 
Yuya Seko
No Relationships to Disclose
 
Hideki Fujii
No Relationships to Disclose
 
Shinichi Aishima
No Relationships to Disclose
 
Masato Yoneda
No Relationships to Disclose
 
Hidenori Toyoda
Honoraria - Abbvie; Eisai; Fujifilm; Gilead Sciences; Kowa Pharmaceutical; Takeda; TERUMO
 
Yoshio Sumida
No Relationships to Disclose
 
Atsushi Nakajima
No Relationships to Disclose
 
Takeshi Okanoue
No Relationships to Disclose